Li Qingchu, Li Cuilin, Li Haoyun, Zeng Liu, Kang Zhiqiang, Mao Yu, Tang Xinyue, Zheng Panpan, He Li, Luo Fang, Li Zhi
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Int J Endocrinol. 2017;2017:3402808. doi: 10.1155/2017/3402808. Epub 2017 Jul 9.
Metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (T2DM). Based on the previous research on and diabetes, we aimed to investigate the distributive characteristic of rs2075604 polymorphism and the potential influence of rs2075604 polymorphism on metformin efficacy among Chinese T2DM patients. There was no significant difference between T2DM patients ( = 64.8%, = 35.2%) and healthy subjects ( = 62.7%, = 37.2%) in rs2075604 genotype and allele frequencies. After 12 weeks of treatment, 62 patients were defined as the responders and 32 patients as nonresponders according to the decrease of HbA1c level. And the GT + TT genotype in rs2075604 can decrease HbA1c level more significantly than the GG genotype. Furthermore, the allele frequency of T in the rs2075604 was higher in the responders than the nonresponders (43.55% versus 26.56%). The T allele in the rs2075604 had a 2.133 times great chance of responding to metformin treatment. In conclusion, this study suggested that the rs2075604 genetic polymorphism was significantly associated with metformin efficacy in Chinese T2DM patients and the carriers of the T allele may gain a better therapeutic metformin efficacy compared with the G allele. This trial is registered with clinical study registration number NCT03155087.
二甲双胍是一种经典的口服抗糖尿病药物，常被推荐作为2型糖尿病（T2DM）的首选治疗药物。基于先前对[具体内容缺失]和糖尿病的研究，我们旨在调查中国T2DM患者中rs2075604多态性的分布特征以及rs2075604多态性对二甲双胍疗效的潜在影响。T2DM患者（[缺失具体数据] = 64.8%，[缺失具体数据] = 35.2%）和健康受试者（[缺失具体数据] = 62.7%，[缺失具体数据] = 37.2%）在rs2075604基因型和等位基因频率方面无显著差异。治疗12周后，根据糖化血红蛋白（HbA1c）水平的下降情况，62例患者被定义为反应者，32例患者为无反应者。rs2075604的GT + TT基因型比GG基因型能更显著地降低HbA1c水平。此外，反应者中rs2075604的T等位基因频率高于无反应者（43.55%对26.56%）。rs2075604的T等位基因对二甲双胍治疗产生反应的可能性是G等位基因的2.133倍。总之，本研究表明rs2075604基因多态性与中国T2DM患者的二甲双胍疗效显著相关，与G等位基因相比，T等位基因携带者可能获得更好的二甲双胍治疗效果。本试验已在临床研究注册编号NCT03155087下注册。
